Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis?. Issue 2 (27th June 2022)

• Record Type: Journal Article
• Authors: Bouffard, Marc A.; Prasad, Sashank; Unizony, Sebastian; Costello, Fiona
• Editors: Costello, Fiona; Prasad, Sashank
• Is Part Of: Journal of neuro-ophthalmology. Volume 42:Issue 2(2022)
• Page Start: 173
• Page End: 179
• Publication Date: 2022-06-27
• Subjects: Neuroophthalmology -- Periodicals; 617.7
• DOI: 10.1097/WNO.0000000000001514
• Languages: English
• ISSNs: 1070-8022

Abstract

Abstract : Background: Despite appropriate use of corticosteroids, an important minority of patients with giant cell arteritis (GCA) develop progressive vision loss during the initial stages of the disease or during corticosteroid tapering. Tocilizumab is the only clearly effective adjunctive treatment to corticosteroids in the management of GCA, but questions regarding its efficacy specifically in the neuro-ophthalmic population and its role in mitigating vision loss have not been broached until recently. Evidence Acquisition: The authors queried Pubmed using the search terms "GCA" and "tocilizumab" in order to identify English-language publications either explicitly designed to evaluate the influence of tocilizumab on the ophthalmic manifestations of GCA or those which reported, but were not primarily focused on, ophthalmic outcomes. Results: Recent retrospective analyses of populations similar to those encountered in neuro-ophthalmic practice suggest that tocilizumab is effective in decreasing the frequency of GCA relapse, the proportion of flares involving visual manifestations of GCA, and the likelihood of permanent vision loss. Data regarding the utility of tocilizumab to curtail vision loss at the time of diagnosis are limited to case reports. Conclusions: Compared with conventional corticosteroid monotherapy, treatment of GCA with both corticosteroids and tocilizumab may decrease the likelihood of permanent vision loss. Further prospective, collaborative investigation between rheumatologists and neuro-ophthalmologists is required to clarify the ophthalmic and socioeconomic impact of tocilizumab on the treatment of GCA.